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Abstract
Objective: We investigated factors associated with masked and white-coat hypertension in a Swiss population-based
sample.
Methods: The Swiss Kidney Project on Genes in Hypertension is a family-based cross-sectional study. Office and 24-hour
ambulatory blood pressure were measured using validated devices. Masked hypertension was defined as office blood
pressure,140/90 mmHg and daytime ambulatory blood pressure$135/85 mmHg. White-coat hypertension was defined as
office blood pressure$140/90 mmHg and daytime ambulatory blood pressure,135/85 mmHg. Mixed-effect logistic
regression was used to examine the relationship of masked and white-coat hypertension with associated factors, while
taking familial correlations into account. High-normal office blood pressure was defined as systolic/diastolic blood pressure
within the 130–139/85–89 mmHg range.
Results: Among the 652 participants included in this analysis, 51% were female. Mean age (6SD) was 48 (618) years. The
proportion of participants with masked and white coat hypertension was respectively 15.8% and 2.6%. Masked
hypertension was associated with age (odds ratio (OR) = 1.02, p = 0.012), high-normal office blood pressure (OR= 6.68, p,
0.001), and obesity (OR= 3.63, p = 0.001). White-coat hypertension was significantly associated with age (OR= 1.07, p,
0.001) but not with education, family history of hypertension, or physical activity.
Conclusions: Our findings suggest that physicians should consider ambulatory blood pressure monitoring for older
individuals with high-normal office blood pressure and/or who are obese.
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Introduction
In the last few decades, the development of techniques that
enable measurement of blood pressure (BP) outside the physician’s
office using either ambulatory or home BP has allowed individuals
to be classified into four BP categories: sustained normotension
(individuals who have normal office and out-of-office BP),
sustained hypertension (individuals who have hypertension by
both methods), white-coat hypertension (individuals who have
office hypertension but normal out-of-office BP), and masked
hypertension (individuals who have out-of-office hypertension but
normal office BP) [1].
The term masked hypertension (MH) was first coined by
Pickering et al in 2002 [2,3]. The prevalence of MH may vary
from 8 to 48% depending on the study methods and population
[4]. Longitudinal studies have demonstrated that individuals with
MH have higher cardiovascular disease (CVD) morbidity than
normotensive persons, independent of other CVD risk factors
[1,5,6]. Moreover, persons with MH have higher BP variability
than normotensive individuals [7], and tend to subsequently
develop sustained hypertension (SH) [8]. Identifying risk factors
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for MH may allow clinicians to select patients who should undergo
ambulatory BP monitoring (ABPM) [4]. It has been previously
shown that male sex [6,9], age [10,11], body mass index (BMI)
[12], smoking and alcohol intake [11], high-normal office BP [11],
and a low educational level [9] are associated with MH in the
general population.
On the other hand, the clinical significance of white-coat
hypertension (WCH) remains debated to this day [13]. Although
the vast majority of studies have shown that individuals with WCH
tend to have the same CVD morbidity as normotensive persons
[14,15,16], some studies have demonstrated that individuals with
WCH can have a CVD event rate comparable to individuals with
sustained hypertension (SH) [17,18], or are at a higher risk of
developing SH with time [19]. If WCH is a truly benign condition,
unnecessarily treating persons with WCH will have both clinical
and financial consequences [13]. Factors that have been shown to
be associated with WCH are age, hypertension of recent onset,
and low education [13,20].
Increasing research has been dedicated to better understanding
the factors associated with MH. However, only a small number of
studies using 24-hour ABPM have been conducted on a
population-based level [6,9,12,16,21,22,23], with some being
performed among individuals with a limited age range. We
explored factors associated with masked hypertension and white-
coat hypertension within the multicultural setting of Switzerland.
We aimed to provide clinically useful indicators for these
conditions in a population- and family-based multicentric sample
of Swiss adults aged 18 years and older.
Methods
Ethics statement
All study participants provided written informed consent. The
SKIPOGH study was approved by the Human Research Ethics
Committee, Lausanne University Hospital and University of
Lausanne (Lausanne, Switzerland), by the Ethics Committee for
the Research on Human Beings, Geneva University Hospitals
(Geneva, Switzerland), and by the Ethics Committee of the
Canton of Bern, (Bern, Switzerland).
Study population and design
SKIPOGH (Swiss Kidney Project on Genes in Hypertension) is
a family and population-based cross-sectional study that examines
the genetic determinants of BP. SKIPOGH is part of the larger
family-based international EPOGH study (European Project on
Genes in Hypertension). SKIPOGH employs the same method-
ology as that implemented and validated in the EPOGH study
[24].
SKIPOGH is a multi-centre study with participants being
recruited in the cantons of Bern and Geneva, and the city of
Lausanne. Detailed methods have been previously described
[25,26]. Briefly, recruitment began in December 2009 and ended
in April 2012 in Lausanne, in October 2012 in Geneva, and in
April 2013 in Bern. Different strategies were used to draw up
random samples of the population in each study centre. Index
cases were randomly selected from the population-based CoLaus
study [27] in Lausanne, and from the population-based Bus Sante´
study in Geneva [28]. In Bern, index participants were randomly
selected using the cantonal phone directory. Inclusion criteria were
as follows: (a) minimum age of 18 years; (b) of European descent
(defined as having both parents and grandparents born in a
restricted list of countries); (c) at least one, and ideally three, first
degree family members also willing to participate in the study.
Participation rate was 20% in Lausanne, 22% in Geneva, and
21% in Bern.
Participants filled in a standardized questionnaire at home. The
questionnaire focused on a variety of issues including lifestyle
habits as well as medical and drug history. The study visit was
performed in the morning after an overnight fast. Electrolytes,
kidney-function test, and blood glucose were measured in local
laboratories using standard clinical laboratory methods. Partici-
pants were also asked to collect a 24-hour urine sample for the
measurement of urinary volume, electrolytes, and the excretion of
albumin, urea and creatinine. The CKD-EPI formula was used to
calculate the estimated glomerular filtration rate (eGFR) [29].
Body weight and height were measured using precision electronic
scales (Seca , Hamburg, Germany).
Blood pressure measurements
BP was measured with a non-mercury auscultatory sphygmo-
manometer (A&D UM-101, A&D Company, Ltd., Toshima Ku,
Tokyo, Japan) that has passed the International Protocol for
validation of BP measuring devices of the European Society of
Hypertension (ESH) [30]. This device has also been internally
validated by our research group [31]. BP was measured after 10
minutes of rest in the sitting position in each arm. Subsequently,
five consecutive BP measurements were taken on the side with the
highest BP [13]. In this paper, each subject’s office BP was defined
as the mean of the last four office BP readings. 24-hour APBM was
measured using a validated Diasys Integra device (Novacor, Rueil-
Malmaison, France) that has fulfilled the validation criteria set
forth by the British Hypertension Society and Association for the
Advancement of Medical Instrumentation (AAMI) protocols [32].
Measurements were taken every 15 minutes during the day, and
every 30 minutes during the night (from 10 pm to 7 am).
Participants were included in the analyses if they had at least
fourteen systolic BP (SBP) and diastolic BP (DBP) measurements
during the day and at least seven readings during the night, in
accordance with ESH recommendations [13]. 75 participants
were excluded due to insufficient 24-hour BP readings. Day and
night periods were obtained from participants’ diaries over the 24-
hour period. BP outliers were identified according to the editing
criteria adopted by A&D software [33] and subsequently excluded
from the analyses. Outliers were defined as SBP .280 mmHg,
SBP ,60 mmHg, DBP .200 mmHg, DBP ,40 mmHg, heart
rate .200 beats/min, heart rate ,40 beats/min, or DBP $ SBP.
If one of the BP measures was categorized as an outlier (e.g. SBP),
then the other measures taken at the same instant in time (e.g.
DBP and heart rate) were also excluded. On average, 3 BP
readings were categorized as outliers per participant over the 24-
hour period. Mean BP readings were subsequently calculated
using the valid 24-hour, daytime, and night-time measurements.
Sustained normotension (NT) was defined as office BP ,140/
90 and daytime ambulatory BP ,135/85 mmHg. MH was
defined as office BP,140/90 mmHg and daytime ambulatory BP
$135/85 mmHg. WCH was defined as office BP $140/
90 mmHg and daytime ambulatory BP ,135/85 mmHg [4,13].
SH was defined as office BP $140/90 mmHg and daytime
ambulatory BP $135/85 mmHg, or if the participant reported
taking an anti-hypertensive medication. Accordingly, individuals
on anti-hypertensive medication (n = 105) were excluded from the
NT, WCH, and MH categories. For certain sensitivity analyses,
SH was re-defined as having both office and ambulatory
hypertension while excluding individuals who were on anti-
hypertensive medication.
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Associated factors
High-normal office BP was defined as an office SBP between
130-139 mmHg and office DBP between 85–89 mmHg [34].
High-normal office BP was only assessed among normotensive
individuals and individuals with MH as, by definition, participants
with WCH and SH already have office hypertension. Smoking was
defined as responding yes to the question ‘‘Do you currently
smoke?’’ Alcohol consumption was defined as consuming at least
one alcoholic beverage per week. BMI was calculated as weight
(kilogram) divided by height squared (meter). BMI categories were
defined as follows: normal-weight (,25 kg/m2), overweight (25–
30 kg/m2), and obesity ($30 kg/m2). Physical activity was
assessed as a continuous variable by asking participants to report
the number of hours per week they spend playing sports.
Albuminuria was defined as a urinary albumin excretion $
20 mg/min [35]. Education was classified into three categories: up
to primary education, secondary education, and higher education
(e.g. university or equivalent). Participants were asked to report if
one of their parents or siblings is known to have hypertension or
has suffered from a myocardial infarction (MI) or stroke.
Analyses
All statistical analyses were conducted using Stata 12.0 (Stata
College Station, TX). Complete case analysis was conducted on
participants from Lausanne and Geneva, and participants from
Bern up until 2011. Differences in baseline characteristics across
BP categories were tested using Fisher’s exact test for categorical
variables and a 3 degrees of freedom likelihood-ratio test from a
linear regression model for continuous variables. The ambulatory
and office means for SBP, DBP, and heart rate were adjusted for
age, sex, BMI, and study centre using mixed linear models, and a
likelihood-ratio test was used to test the differences across BP
categories, while taking familial correlations into account. Mixed-
effect logistic regression was used to examine the relationship of
MH, WCH, and SH with associated factors, while also taking
familial correlations into account. For the latter analyses,
normotension was used as the reference category.
Results
Complete case analysis of the data resulted in 652 participants
with 51% of the sample population being female. Mean age was
48 (618) years. 15.0% of individuals had office hypertension (i.e.
had an office BP $140/90 mmHg) and 28.2% had daytime
ambulatory hypertension (i.e. had a daytime ambulatory BP $
135/85 mmHg). Table 1 displays the descriptive characteristics of
the study population for each BP category. Individuals with WCH
were, on average, twenty years older than normotensive individ-
uals, but had similar age as individuals with SH. 40.8% of MH
individuals had high-normal office BP as compared to 7.8% of
normotensive individuals (p,0.001).
Figures 1, 2, 3 display mean ambulatory and office SBP, DBP,
and heart rate by BP category (exact values of means, standard
errors and p values can be found in Table S1). Individuals with
MH and SH tended to have the highest 24-hour BP values as
compared to the other BP categories. As expected, individuals with
WCH had the highest office BP levels (p,0.001). Individuals with
MH had the highest 24-hour, daytime, and night-time heart rate
(p,0.01).
Univariate and multivariable logistic regression analyses were
performed to assess the associations between MH and selected
factors, with normotensive individuals acting as the reference
group (Table 2). In multivariable analysis, age and overweight/
obesity were positively associated with MH (odds ratio (OR): 1.02,
p = 0.012 for age; OR: 3.63, p= 0.001 for obesity). The odds of
having MH were 6.7 times greater among individuals with high-
normal office BP (p,0.001) as compared to individuals with an
office BP ,130/85 mmHg. Physical activity (hours per week) was
inversely associated with MH (OR: 0.92; 95% confidence interval
(CI): 0.85–0.99). There was no statistically significant association
for smoking, alcohol consumption, or educational level. Moreover,
Table 1. Descriptive statistics of the study population (n = 652).
Normotension White-coat hypertension Masked hypertension
Sustained
hypertension Pa
Proportion 386 (59.2) 17 (2.6) 103 (15.8) 146 (22.4)
Age (years) 41.9 (16.9) 61.3 (15.6) 48.7 (13.6) 62.0 (12.3) ,0.001
Sex (female) 216 (56.0) 7 (41.2) 43 (41.8) 64 (43.8) 0.012
BMI (kg/m2) 23.7 (3.8) 26.5 (3.9) 26.5 (4.4) 27.1 (4.0) ,0.001
eGFR (ml/min/1.73 m2) 100.6 (17.1) 87.2 (15.2) 93.9 (17.2) 87.5 (16.0) ,0.001
Smoking (yes) 95 (24.6) 1 (5.9) 20 (19.4) 29 (19.9) 0.199
Alcohol consumption (yes) 234 (60.6) 11 (64.7) 67 (65.1) 99 (67.8) 0.464
High-normal office BP 30 (7.8) 42 (40.8) ,0.001
Microalbuminuria $20 mg/min 17 (4.4) 2 (11.8) 9 (8.7) 12 (8.2) 0.089
Education (up to primary) 49 (12.7) 3 (17.7) 9 (8.7) 24 (16.4) 0.542
Secondary 196 (50.8) 8 (47.1) 53 (51.5) 77 (52.7)
Higher education 141 (36.5) 6 (35.3) 41 (39.8) 45 (30.8)
Physical activity (hours/week) 3.1 (4.4) 2.7 (3.0) 2.2 (2.7) 2.3 (2.9) 0.034
Family history of hypertension 182 (47.2) 11 (64.7) 48 (46.6) 91 (62.3) 0.008
Family history of MI or stroke 85 (22.0) 7 (41.2) 35 (34.0) 75 (51.4) ,0.001
Data are mean (standard deviation) or n (%).
aComparison between the four blood pressure categories; BMI: body mass index, eGFR: estimated glomerular filtration rate, BP: blood pressure, MI: myocardial
infarction.
doi:10.1371/journal.pone.0092522.t001
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Figure 1. Mean (and standard error) ambulatory and office systolic blood pressure (SBP) by blood pressure category.
doi:10.1371/journal.pone.0092522.g001
Figure 2. Mean (and standard error) ambulatory and office diastolic blood pressure (DBP) by blood pressure category.
doi:10.1371/journal.pone.0092522.g002
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we did not find a significant association between MH and fasting
serum glucose, serum sodium and potassium, 24-hour urinary
sodium and potassium excretion, microalbuminuria, and eGFR
(results not shown).
Table 3 displays the relationship between WCH and associated
factors. As only one person reported smoking among individuals
with WCH, smoking was not included as a covariate in these
analyses. Similarly to MH, WCH was positively associated with
age (p,0.001).
The association between SH and selected factors is presented in
Table 4. There was a positive association between SH and age,
obesity, and a family history of hypertension, MI, or stroke (p,
0.05). Physical activity was inversely associated with SH (OR: 0.91;
95% CI: 0.85–0.99).
We also conducted sensitivity analyses to explore whether the
factors associated with MH differed by study centre. Due to the
limited number of individuals with MH in our study, we ran the
analyses while grouping two study centres at a time (e.g. Geneva
and Bern, Geneva and Lausanne, Lausanne and Bern). The
factors associated with MH were very similar to our findings
including all three centres (results not shown). We could not
perform similar sensitivity analyses for WCH due to the limited
number of participants identified as white-coat hypertensives.
Discussion
Our study is the first to estimate the proportion of MH in a
family- and population-based study in Switzerland. We found that
one in six individuals in our sample had MH, a finding
comparable to other population-based studies [12,21,22,23].
Although the frequency of WCH in our study (3%) was lower
than that normally reported in the literature, other population-
based studies have also found a prevalence within the range of 3–
5% [12,36,37]. This low WCH proportion may be attributable to
the relatively young age of our study population, as WCH tends to
occur more often in older individuals [38], as well as the clinical
settings in which office BP was measured in this study (after ten
minutes of rest). Moreover, mean office BP was calculated using
the last four BP readings whilst disregarding the first BP
measurement. Correspondingly, individuals with WCH were, on
average, 20 years older than normotensive individuals in our
study. Moreover, it has been shown that WCH is associated with a
previous diagnosis of hypertension [38], and as the current study is
population-based, only 16% of individuals reported being on anti-
hypertensive medication. It should also be noted that the
proportion of MH and WCH is directly related to the cut-offs
used to define normal office and ambulatory BP [4]. Although
most studies tend to use the thresholds of 140/90 mmHg for office
BP and 135/85 mmHg for daytime ambulatory BP, some studies
set their thresholds based on the population studied, use arbitrary
thresholds, or employ thresholds that are identical for both office
and ambulatory BP [4].
A growing body of evidence has found that ABPM is better
correlated with target organ damage than office BP measurement
[15], and that persons with MH have a CVD risk comparable to
those with SH [14]. The odds of having MH was seven times
greater among participants who had a high-normal office BP, a
finding consistent with previous reports [3,10,11,39]. Moreover,
the proportion of MH among individuals with high-normal office
BP was 31.8% as compared to 11.7% among individuals with an
office BP of less than 130/85 mmHg. High-normal office BP may
thus be of important clinical utility, as it is easy to measure and
appears to be strongly associated with MH, thereby aiding
physicians in selecting patients for ABPM. Shimbo et al
hypothesized that although both ambulatory and office BP
increase with age, ambulatory hypertension may precede office
Figure 3. Mean (and standard error) ambulatory and office heart rate (HR) by blood pressure category.
doi:10.1371/journal.pone.0092522.g003
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hypertension, whereas office BP rises but remains within the
normal office BP range in the early stages [3]. In our study, 41% of
individuals with MH had high-normal office BP. It is presumed
that the office BP of these individuals will eventually increase
leading to SH [3], suggesting that it would be advisable to screen
these individuals for MH. Notably, just over half of the global
burden of CVD that is attributable to BP occurs in individuals
with high-normal BP [40]. Of note, in contrast to some earlier
studies, MH in this paper was considered only among untreated
individuals.
Some studies [11,39], although not all [12,16,41], have found
that smoking and alcohol consumption are correlated with MH
and WCH. In our study, we did not find a significant association
between smoking and alcohol consumption and BP status. In line
with the existing literature [11,22,39], persons who were
overweight or obese were more likely to have MH and SH.
Moreover, physical activity was inversely associated with MH,
consistent with a previous study that also found that MH was
associated with a low physical activity score among nonsmokers
[41].
We found that individuals with MH and SH had the highest
ambulatory BP whereas individuals with WCH had the highest
office BP. Interestingly, the mean ambulatory DBP of masked
hypertensives was significantly higher than that of SH individuals.
When treated individuals were excluded from the SH category,
this was no longer the case. We also found that individuals with
MH had the highest ambulatory heart rate. It has been postulated
that MH is associated with a sympathetic overdrive, although the
exact mechanisms underlying this sympathetic activation have to
be further clarified [38,42]. In our study, individuals with WCH
had the highest office heart rate, which is compatible with previous
results showing that individuals with WCH have an increased
sympathetic activity [23,43].
Our study has some limitations. The cross-sectional nature of
this study limits inference on causality. There were relatively few
participants who were classified as having WCH, limiting the
statistical analyses that may be performed on this sub-group.
Likewise, we were unable to stratify individuals in the SH category
by treatment status due to the low number of participants who had
SH and were not on anti-hypertensive medication. Participation
rate was relatively low, raising the issue of selection bias and thus
limiting the external validity of our results. However, there was no
difference in terms of age and sex distribution between the
participants to this study and those of the population-based sample
from which they were drawn [25]. Moreover, each study centre
used a different strategy to select study participants, which implies
that selection biases, if any, are likely to differ across centers. Our
sensitivity analyses demonstrated that results were similar when
restricting the analyses to two centres instead of three centres.
Furthermore, the factors we found to be associated with MH were
similar to those previously published, which suggests that our
findings have reasonable external validity. Strengths of this study
include its population-and family-based nature and the relatively
large sample size.
Conclusion
We found that individuals with MH tend to share similar
characteristics as patients with SH. Although there is currently a
lack of randomized controlled trials that have investigated the
benefits of treating patients with MH, it is plausible that by
identifying individuals with MH, cardiovascular complications and
target organ damage may potentially be avoided if management of
hypertension is based on ambulatory BP [16]. Our results suggest
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that clinicians should suspect MH in an older (and/or overweight)
patient with high-normal office BP.
Supporting Information
Table S1 Mean ambulatory and office systolic blood pressure
(SBP), diastolic blood pressure (DBP), and heart rate (HR) by
blood pressure category.
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